Navigation Links
Butrans® (Buprenorphine) Transdermal System CIII Pivotal Phase 3 Data Published in the Journal of Pain and Symptom Management
Date:10/26/2011

s multi-center, randomized, double-blind, placebo-controlled, parallel-group study employed an enriched design which included a run-in phase of up to 27 days in which 1,024 opioid-naive patients with moderate-to-severe chronic low back pain who were suboptimally responsive to their non-opioid therapy received open-label treatment with Butrans.  

Opioid-naive patients were defined as patients who were receiving less than 5 mg of oxycodone or the equivalent in the 14 days prior to screening, and who did not have a history of daily opioid use of greater than or equal to 5 mg of oxycodone or the equivalent for three months prior to screening, and who, in the opinion of the investigator, were not opioid dependent at time of entry to the study, had not benefitted from or had not tolerated non-opioid therapy, and were deemed to be appropriate candidates for an around-the-clock opioid analgesic regimen.  

Of the 1,024 patients who entered the open-label, dose-titration period, 53% were able to titrate to a tolerable and effective dose of Butrans and were randomized into a 12-week, double-blind treatment period.  Twenty-three percent (23%) of patients discontinued due to an adverse event from the open-label titration period and 14% discontinued due to lack of a therapeutic effect.  Of the patients who were randomized, the mean (SE) Numerical Rating Scale pain scores were 7.2 (0.08) and 7.2 (0.07) at screening and 2.6 (0.08) and 2.6 (0.07) at pre-randomization (beginning of double-blind phase) for the Butrans and placebo groups, respectively.

A total of 541 patients were randomized to receive Butrans (10 or 20 mcg/hour, N=257) or placebo (N=284) in a double-blinded fashion, based on tolerability and analgesic response at the end of the open-label titration period.  During the first seven days of double-blind treatment patients were allowed up to two tablets per day of immediate-release oxycodone 5 mg as supplemental analgesia to m
'/>"/>

SOURCE Purdue Pharma L.P.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain
2. Purdue Pharma L.P. to Present Data From Clinical Program for Butrans™ (buprenorphine) Transdermal System CIII at PAINWeek® 2010
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial
5. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
6. Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
9. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
10. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
11. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... , April 28, 2015  Illnesses know no work schedule ... places of business. If you,ve ever woken up the morning ... sick as the proverbial dog, or if you,ve been putting ... how to fit it into your schedule, you,ve experienced this ... House Call Doctor Los Angeles offers an alternative for busy ...
(Date:4/28/2015)... 28, 2015 UPM Pharmaceuticals, an independent drug ... prestigious "2015 Industry Choice Award" in the Mid-sized and ... Life Science Leader magazine during the annual CMO ... York City on March 18, 2015. The ... service organizations based on survey responses from thousands of ...
(Date:4/28/2015)... 28, 2015  The Physician-Patient Alliance for Health ... , RRT has joined the Physician-Patient Alliance Board ... well-respected Registered Respiratory Therapist who has practiced in the ... for his excellent work on critical patient safety issues. ... Care (AARC) at various conferences addressing the need ...
Breaking Medicine Technology:Your Health and Your Schedule Should not be at War 2UPM Pharmaceuticals Awarded The 2015 Industry Choice Award for Mid-sized and Emerging Pharma 2Noted Respiratory Therapist and AARC Representative Gene Gantt Joins Physician-Patient Alliance for Health & Safety Advisory Board 2
(Date:4/28/2015)... Pittsburgh, PA (PRWEB) April 28, 2015 ... by Blair A. Jobe, MD, FACS , has ... replacing esophageal tissue with extracellular matrix (ECM) can help ... lethal form of esophageal cancer. , ECM is a ... for cell attachment and migration and signals that guide ...
(Date:4/28/2015)... 2015 As the Muscular Dystrophy ... services programs, the organization has hired Scientific Program ... MDA from Fidelity Biosciences Research Initiative where, as ... in neurodegenerative diseases such as Alzheimer’s Disease, and ... time at Fidelity, she was a junior faculty ...
(Date:4/28/2015)... 2015 Researchers from four US medical ... a steroid prior to pemetrexed (Alimta) chemotherapy may keep ... Click here to read the full story on ... Raabe College of Pharmacy in Ohio, Stanford Cancer Institute ... Healthcare in Kentucky gave a single dose of dexamethasone ...
(Date:4/28/2015)... 2015 SeniorCare.com has published the ... reality problem Americans have regarding aging and long-term care ... care services as they age, 63% of Americans do ... In the report, Carol Marak of SeniorCare.com interviewed 44 ... Health Care Association and The Scan Foundation. The experts ...
(Date:4/28/2015)... Enrollment in programs designed to coordinate ... in April, according to the editors of Atlantic ... Eligibles Database , an online subscription resource that ... community. This is a 14% increase since the ... January, but only covers about a quarter of ...
Breaking Medicine News(10 mins):Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 2Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 3Health News:MDA Adds Neurological Disease Expert to Research Team 2Health News:MDA Adds Neurological Disease Expert to Research Team 3Health News:Study Finds New Regimen May Ward Off Skin Rash from Common Mesothelioma Drug, According to Surviving Mesothelioma 2Health News:SeniorCare.com Report: America Has a Major Misconception on Aging 2Health News:Enrollment in Duals Programs Increases 14%, New AIS Database Finds 2
... complicated. Thomas Jefferson University biochemistry researchers have shown ... insect molting hormone doesn,t activate and repress genes as once ... out-competed by a heme-binding receptor to repress the same genes ... For the last 20 years, the nuclear receptor known ...
... U.S. Food and Drug Administration and the National Institutes ... of tobacco users to monitor and assess the behavioral ... The initiative, called the Tobacco Control Act National Longitudinal ... collaboration on tobacco regulatory research since Congress granted FDA ...
... and diagnosis of open angle glaucoma important so that treatment ... developing to prevent or avoid further vision loss. Writing in ... Engineering and Informatics , researchers in the US have analyzed ... so that patients can be screened at an earlier stage ...
... , THURSDAY, Oct. 6 (HealthDay News) -- ,Anemia ... have different types of surgery, not just heart operations, a ... anemia have worse outcomes after heart surgery, but anemia,s impact ... deficient in red blood cells. For the new ...
... had been given DES, the first synthetic form of estrogen, ... in the womb (in utero) is associated with many reproductive ... conditions. The results of this analysis, conducted by researchers at ... of Health, and collaborators across the country, were published Oct. ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, Oct. ... forms of multiple sclerosis appears to reduce relapse rates and ... 3 trial. The experimental drug, teriflunomide, is one of ... and may, if approved, be a good choice for many ...
Cached Medicine News:Health News:Nuclear receptors battle it out during metamorphosis in new fruit fly model 2Health News:FDA and NIH announce joint study on tobacco use and risk perceptions 2Health News:Detecting glaucoma before it blinds 2Health News:Anemia Could Add to Surgical Risks 2Health News:Women exposed to diethylstilbestrol in the womb face increased cancer risk 2Health News:Women exposed to diethylstilbestrol in the womb face increased cancer risk 3Health News:Experimental MS Drug Shows Promise 2Health News:Experimental MS Drug Shows Promise 3
... Introducing the new large ... new handpieces function as both ... the ultimate in flexibility. Its ... always wanted with the security ...
... 7600 Oscillating Saw offers unparalleled ... thanks to its 14.4V NiMH ... head may be rotated into ... any plane and will accept ...
... Breakthrough in Battery Powered Orthopedic Systems., ... new addition to the Hall® Surgical line ... System is the first and only software ... market. It is a full-function orthopedic power ...
... Introducing the new large ... Our new handpieces function ... electric instruments, offering the ... the versatility the industry ...
Medicine Products: